Navigation Links
Dragon Pharma announces date of special meeting
Date:6/28/2010

VANCOUVER, June 28 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" TSX: DDD; OTCBB: DRUG) announced that its Special Meeting of Shareholders will be held on Tuesday, July 20, 2010 at 10:30 a.m., Pacific Time at the Company's corporate office located at Suite 310, 650 West Georgia Street, Vancouver, British Columbia, Canada V6B 4N9. Only shareholders of record of as of May 28, 2010 will be entitled to vote upon the proposed Agreement and Plan of Merger by and among Dragon, Chief Respect Limited, a Hong Kong corporation, Datong Investment Inc., a Florida corporation and subsidiary of Chief Respect Limited, and Mr. Yanlin Han, pursuant to which Datong Investment Inc. will merge with and into Dragon and each holder of Dragon shares of common stock, excluding Mr. Han, will receive $0.82 per share. Notice of the meeting and accompany proxy statement are being mailed to shareholders on June 28, 2010.

Additional Information and Where to Find It

In connection with the proposed merger, the Company has filed with the Securities and Exchange Commission (the "SEC") a Schedule 13E-3, and a definitive proxy statement for the meeting of stockholders of the Company to be convened to approve the merger. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, DRAGON'S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. Stockholders may obtain a free copy of the proxy statement, and other documents filed by us with the SEC, at the SEC's web site at http://www.sec.gov. Free copies of the proxy statement and our other filings with the SEC may also be obtained from us. Free copies of our filings may be obtained by directing a request to Dragon Pharmaceutical, Inc., 650 West Georgia Street, Suite 310, Vancouver, British Columbia, Canada V6B 4N9 Attention: Maggie Deng, Secretary. Copies of the proxy statement may also be obtained at our website, www.dragonpharma.com.

About Dragon Pharmaceutical Inc.

Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading manufacturer and distributor of a broad line of high-quality antibiotic products including Clavulanic Acid, an API to combine with Amoxicillin to fight resistance, and 7-ACA, a key intermediate to produce cephalosporin antibiotics, and formulated cephalosporin antibiotic drugs. To learn more about Dragon Pharmaceutical Inc., please visit www.dragonpharma.com.


'/>"/>
SOURCE Dragon Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dragon Pharma reports 2010 first quarter financial results
2. Dragon Pharma Announces Results of 2009 Annual General Meeting
3. Dragon Pharma Announces June 21, 2009 for 2009 Annual Shareholders Meeting
4. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
5. Dragon to Present at BioContact Quebec 2008
6. Dragon Pharma Announces Results of the Annual General Meeting
7. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
8. 3SBio Inc. to Present at The Oppenheimer 2nd Annual China Dragon Call Conference
9. Dragon Pharma announces 2007 full year financial results
10. Dragon retains leading investor relations firm
11. Dragon announces new product launch; increase in annual production output capacity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... 27, 2017  Kinexum, a distinguished resource for research, ... the appointment of Thomas C. Seoh as ... M.D., Kinexum founder, who becomes Executive Chairman and will ... clients. Thomas Seoh commented, "I ... mission and lead the firm,s remarkable team of life ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 ... extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific ... offer NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
(Date:4/26/2017)...  Genisphere LLC, provider of the 3DNA ® ... and sponsored research agreement with the University of ... overall goal of the partnership is to study ... and formulations after in vivo administration. ... as well as inflammatory responses, demonstrating various methods ...
(Date:4/25/2017)... R.I. , April 25, 2017 ... Inc. ("EpiVax") has licensed its novel immune-modulating technology to ... autoimmune disease and allergy. Tregitopes, pronounced ... in human immunoglobulin by EpiVax CEO Annie ... Similar to intravenous immunoglobulin G, an autoimmune disease ...
Breaking Biology Technology:
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
(Date:3/20/2017)... 20, 2017 PMD Healthcare announces the release ... Wellness Management System (WMS), a remote, real-time lung health ... PMD Healthcare is a Medical Device, Digital Health, and ... to creating innovative solutions that empower people to improve ... focus, PMD developed the first ever personal spirometer, Spiro ...
Breaking Biology News(10 mins):